Sana Biotechnology Inc. (SANA)
Sana Biotechnology Statistics
Share Statistics
Sana Biotechnology has 225.03M shares outstanding. The number of shares has increased by 1.28% in one year.
| Shares Outstanding | 225.03M |
| Shares Change (YoY) | 1.28% |
| Shares Change (QoQ) | 0.36% |
| Owned by Institutions (%) | 67.13% |
| Shares Floating | 125.16M |
| Failed to Deliver (FTD) Shares | 750 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 50.28M, so 22.52% of the outstanding shares have been sold short.
| Short Interest | 50.28M |
| Short % of Shares Out | 22.52% |
| Short % of Float | 41.07% |
| Short Ratio (days to cover) | 3.57 |
Valuation Ratios
The PE ratio is -1.41 and the forward PE ratio is -3.45. Sana Biotechnology's PEG ratio is 0.07.
| PE Ratio | -1.41 |
| Forward PE | -3.45 |
| PS Ratio | 0 |
| Forward PS | 2.2 |
| PB Ratio | 1.5 |
| P/FCF Ratio | -1.47 |
| PEG Ratio | 0.07 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Sana Biotechnology Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.54, with a Debt / Equity ratio of 0.38.
| Current Ratio | 3.54 |
| Quick Ratio | 3.54 |
| Debt / Equity | 0.38 |
| Total Debt / Capitalization | 27.33 |
| Cash Flow / Debt | -2.37 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.06% and return on capital (ROIC) is -79.12%.
| Return on Equity (ROE) | -1.06% |
| Return on Assets (ROA) | -0.53% |
| Return on Capital (ROIC) | -79.12% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1,375,046.39 |
| Employee Count | 194 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -81.6% in the last 52 weeks. The beta is 1.64, so Sana Biotechnology's price volatility has been higher than the market average.
| Beta | 1.64 |
| 52-Week Price Change | -81.6% |
| 50-Day Moving Average | 2.85 |
| 200-Day Moving Average | 3.87 |
| Relative Strength Index (RSI) | 34.29 |
| Average Volume (20 Days) | 7.67M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -272.72M |
| Net Income | -266.76M |
| EBITDA | -272.72M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.16 |
Balance Sheet
The company has 127.57M in cash and 94.2M in debt, giving a net cash position of 33.37M.
| Cash & Cash Equivalents | 127.57M |
| Total Debt | 94.2M |
| Net Cash | 33.37M |
| Retained Earnings | -1.6B |
| Total Assets | 501.02M |
| Working Capital | 115.38M |
Cash Flow
In the last 12 months, operating cash flow was -223.15M and capital expenditures -33.43M, giving a free cash flow of -256.58M.
| Operating Cash Flow | -223.15M |
| Capital Expenditures | -33.43M |
| Free Cash Flow | -256.58M |
| FCF Per Share | -1.11 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SANA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -63.04% |
| FCF Yield | -61.97% |
Analyst Forecast
The average price target for SANA is $9, which is 389.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $9 |
| Price Target Difference | 389.1% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -4.68 |
| Piotroski F-Score | 2 |